- Novel, potent anti-CD39 antibody, IPH52, validated in
preclinical models.
Innate Pharma and OREGA Biotech today presented preclinical data on
IPH52, a new CD39 checkpoint inhibitor program, at the American
Association for Cancer Research (AACR) Annual Meeting 2016 in New
Orleans, Louisiana, USA.
Poster #3222 presents IPH52, Innate's humanized
anti-CD39 blocking antibody. This novel antibody exhibits high
affinity and specificity for CD39 and potently inhibits ATPase
activity in in vitro assays and ex vivo models with patient
biopsies. In a murine tumor model, treatment with anti-CD39
antibody results in a significant decrease in tumor volume, and
improved survival.
Poster #3218 presents for the first time the
impact of CD39 disruption on the efficacy of other cancer
therapeutics by comparing their effects in wildtype versus CD39
knock-out mice. The results revealed that CD39 deficiency
sensitized to anti-PD1 treatment in animals that failed to respond
to anti-PD-1 treatment. The antitumor efficacy of CD39 disruption
is further improved when combined with an immunogenic chemotherapy.
In animals bearing PD-1 insensitive tumors, combination of
immunogenic chemotherapy, anti-PD1 antibody and CD39 disruption led
to complete tumor eradication and long term protection (specific
anti-tumor immunity) in most animals. The efficacy of an
ADCC-inducing cytotoxic antibody was also improved in CD39
knock-out mice compared to wildtype.
Nicolai Wagtmann, CSO of Innate Pharma, said:
"Taken together, the data presented by Innate and our partner OREGA
Biotech form a very promising body of evidence supporting the
development of this new, first-in-class checkpoint inhibitor
antibody. The results presented today raise exciting perspectives
for the development of IPH52, both as single-agent and in
combination with other checkpoint inhibitors, and we are eager to
now take this first-in-class candidate forward into the preclinical
development phases".
Jeremy Bastid, COO of OREGA Biotech, further
commented: "CD39 mediates immunosuppression through a different
mechanism than other immune checkpoints and may broadly impede the
efficacy of cancer therapies. The exciting data released today
using both antibody blockade and genetic CD39 deficiency shed light
on the capacity of CD39 disruption to drive antitumor immune
responses, either alone or in combination with PD-1 checkpoint
blockers, ADCC antibodies and immunogenic chemotherapy, suggesting
broad development potential".
***** Reminder:
Nicolai Wagtmann, Chief Scientific Officer of
Innate Pharma, will hold a conference call to the attention
of analysts and portfolio managers to discuss the data published
and Company's innovative pipeline.
Time and dial in: Tuesday, April 19th 10:30am
Eastern Time USA: 888 504 7963 International:
+1 719 325 2452 Access code: 1890466 Webcast:
http://urlz.fr/3pxC
*****
About IPH52:
IPH52 is an anti-CD39 antibody licensed from
OREGA Biotech. CD39 is a membrane-bound extracellular enzyme
overexpressed on both regulatory T cells and several cancer types.
It plays a major role in promoting immunosuppression through the
pathway degrading adenosine triphosphate (ATP) into adenosine.
Within the tumor microenvironment, ATP promotes immune
cell-mediated killing of cancer cells. In contrast, adenosine
accumulation causes immune suppression and dysregulation of immune
cell infiltrates resulting in tumor spreading.
Blockade of CD39 may therefore stimulate
anti-tumor immunity across a wide range of tumors[*] by promoting
the accumulation of ATP and preventing the production of adenosine
in the tumor microenvironment[1]. IPH52 is a CD39-blocking antibody
aiming at restoring a pro-inflammatory micro-environment and is
currently in preclinical development.
About Innate Pharma
Innate Pharma S.A. is a biopharmaceutical
company discovering and developing first-in-class therapeutic
antibodies for the treatment of cancer and inflammatory
diseases.
Innate Pharma specializes in immuno-oncology, a
new therapeutic field that is changing cancer treatment by
enhancing the capability of the body's own immune cells to
recognize and kill cancer cells.
The Company has pioneered the development of
antibodies that block inhibitory checkpoint receptors on NK cells.
Today, Innate Pharma has three first-in-class antibodies in
clinical development in immuno-oncology and a pipeline of
preclinical candidates to novel targets and mechanisms.
Its innovative approach has translated into
alliances with leaders in the biopharmaceutical industry such as
Bristol-Myers Squibb and AstraZeneca, Sanofi and Novo Nordisk
A/S.
Based in Marseille, France, Innate Pharma had
118 employees as at December 31, 2015. The company is listed on
Euronext Paris.
Learn more about Innate Pharma at
www.innate-pharma.com.
About OREGA Biotech
OREGA Biotech specializes in the discovery and
the development of first-in-class monoclonal antibodies for cancer
immunotherapy. With a specific focus on tumor microenvironment,
OREGA's Target Discovery Program aims at discovering and validating
novel clinically-relevant cancer targets.
Incepted in 2010, OREGA Biotech is based on the
research conducted by its academic cofounders Nathalie Bonnefoy,
Armand Bensussan and Jean-François Eliaou. OREGA's business
strategy is to bring its R&D programs up to preclinical proof
of concept, IND or early clinical stages and then to license them
out to larger biotech or pharmaceutical companies. Funded
by initiative Octalfa, SHAM Innovation Santé, Rhône-Alpes
Création and INSERM-Transfert Initiative, the company is managed by
Gilles Alberici, CEO and Jeremy Bastid, COO.
For more
information: www.orega-biotech.com.
Practical Information about Innate Pharma's
shares:
ISIN
code Ticker code |
FR0010331421 IPH |
Disclaimer:
This press release contains certain
forward-looking statements. Although the company believes its
expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ
materially from those anticipated. For a discussion of risks and
uncertainties which could cause the company's actual results,
financial condition, performance or achievements to differ from
those contained in the forward-looking statements, please refer to
the Risk Factors ("Facteurs de Risque") section of the Document de
Reference prospectus filed with the AMF, which is available on the
AMF website or on Innate Pharma's website.
This press release and the information contained
herein do not constitute an offer to sell or a solicitation of an
offer to buy or subscribe to shares in Innate Pharma in any
country.
For additional information, please
contact:
Innate Pharma |
ATCG
Press |
Laure-Hélène Mercier Director, Investor Relations Tel.: +33 (0)4 30
30 30 87 investors@innate-pharma.com |
Marie
Puvieux (France) Mob: +33 (0)6 10 54 36 72 Jean-Medhi Grangeon
(ROW) Mob: +33 (0)6 62 22 00 24 |
|
presse@atcg-partners.com |
|
|
OREGA Biotech Jeremy
Bastid Chief Operating Officer Tel.: +33 (0)4 37 49 87 20
jeremy.bastid@orega-biotech.com |
|
[*] CD39 is expressed in several human cancers,
including kidney, lung, ovarian, pancreatic, thyroid, testicular,
endometrial, and prostate tumors, as well as in lymphoma and
melanoma.
[1] Bastid et al., Cancer Immunol Res.
2015 ; Bastid et al., Oncogene 2013
IPH AACR 2016 IPH52
http://hugin.info/155662/R/2004767/740322.pdf
HUG#2004767
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024